Close Menu


Myriad's shares climbed a day after it released its fourth-quarter and fiscal 2009 results. Its EPS beat analysts' estimates for the quarter, and Myriad's shares were upgraded by an investment bank.

More OB/GYN sales reps, expanded direct-to-consumer marketing campaigns, and more company-hired physicians reaching out to other doctors are a few “initiatives [that] will be beneficial to the company in combating this weak economy,” Myriad CEO Peter Meldrum said during an earnings call this week.

By instituting a prior notification policy and placing Myriad in charge of determining which patients get tested, United Healthcare can monitor more closely which of its policy holders are receiving testing on BRACAnalysis.

The slowdown in its second-half revenues was noted by Myriad in early July.

According to Satoris, the 189-marker panel covers the "most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development … [and] and thus provide researchers with critical biological information plus leads for further study."

In a motion-to-dismiss memorandum, the defendants call ACLU's case "a thinly veiled attempt to challenge the validity of patents," and accuse the plaintiffs of seeking nothing more than "an advisory opinion in support of an anti-gene patent agenda."

The privately held molecular diagnostics firm will distribute RBM's pnale of biomarkers, which complements its own recently launched panels for neurological conditions.

The defendants recently filed a motion to dismiss the suit, which challenges the practice of gene patenting. The court is scheduled to hear the motion to dismiss later next month.

Affymetrix's shares increased nearly 50 percent during the month on the strength of its Q2 results, while Myriad and Celera each dropped more than 20 percent as they said their respective quarterly revenues would be lower than previously expected.

Myriad Genetics' shareholders received shares in the pharma spin off. The firm also said it had retained the rights to claim $400 million in tax deductions.


A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.

NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.

In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.

In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.